The stock of Dermata Therapeutics Inc (DRMA) has gone down by -18.54% for the week, with a -34.43% drop in the past month and a -40.70% drop in the past quarter. The volatility ratio for the week is 11.41%, and the volatility levels for the past 30 days are 12.57% for DRMA.. The simple moving average for the past 20 days is -28.22% for DRMA’s stock, with a -46.78% simple moving average for the past 200 days.
Is It Worth Investing in Dermata Therapeutics Inc (NASDAQ: DRMA) Right Now?
Company’s 36-month beta value is 0.61.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DRMA is 3.99M, and currently, short sellers hold a 4.73% ratio of that floaft. The average trading volume of DRMA on April 10, 2025 was 1.65M shares.
DRMA) stock’s latest price update
Dermata Therapeutics Inc (NASDAQ: DRMA) has experienced a decline in its stock price by -3.74 compared to its previous closing price of 0.84. However, the company has seen a fall of -18.54% in its stock price over the last five trading days. accessnewswire.com reported 2025-03-27 that SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) (“Dermata,” or the “Company”), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company’s common stock, having exercise prices of $1.58 and $4.91 per share, issued by Dermata in September 2024 (with respect to 3,825,138 warrants) and May 2024 (with respect to 1,009,332 warrants), at a reduced exercise price of $1.284 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File Nos.
DRMA Trading at -30.65% from the 50-Day Moving Average
After a stumble in the market that brought DRMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.54% of loss for the given period.
Volatility was left at 12.57%, however, over the last 30 days, the volatility rate increased by 11.41%, as shares sank -33.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.96% lower at present.
During the last 5 trading sessions, DRMA fell by -18.54%, which changed the moving average for the period of 200-days by -68.50% in comparison to the 20-day moving average, which settled at $1.1235. In addition, Dermata Therapeutics Inc saw -40.26% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for DRMA
The total capital return value is set at -8.02. Equity return is now at value -310.44, with -213.46 for asset returns.
Currently, EBITDA for the company is -12.51 billion with net debt to EBITDA at 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.79.
Conclusion
In a nutshell, Dermata Therapeutics Inc (DRMA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
